NEWS. Sciety supports innovative companies in life science and digital health. We help them grow and become successful, so that scientific breakthroughs in medicine and technology can become available to people all over the world. During the fall we continued our journey towards this goal, together with our portfolio companies.
NEWS. On November 9, 2023, Sciety invited its investor network to an exclusive event on the theme of future scenarios and opportunities within life science. The evening featured a panel discussion on data-driven precision medicine with Tommi Unkuri, Partner and Co-founder of Summa Equity; Mattias Häggblom, Sector Head for Healthcare,
PRESS RELEASE. Sciety och Sciety Venture Partners have invested SEK 54 million in Neogap Therapeutics (Neogap), a Swedish clinical-stage biotech company that develops personalised immunotherapy for cancer treatment with the help of two emerging technologies. The company has also been awarded roughly SEK 29 million in innovation funding from the
PRESS RELEASE. Sciety’s portfolio company PharmNovo, a Swedish pharmaceutical company based in Lund, reports positive results in its clinical phase I study of a drug candidate for nerve pain – an area currently lacking safe and effective treatments. The company announces that the headline results of the study show that
INSIGHT. In recent years, we have seen a clear trend of smaller life science companies hiring contract research organizations, or CROs, to manage their preclinical and clinical studies. This trend is driven, among other things, by increased access to capital for early pharmaceutical companies in recent years. Some of
NEWS. In response to the increasing demand for Sciety’s services, we are happy to announce the addition of three new Communication Specialists to our team. At Sciety, we believe in the importance of clear investor communication. Communication is a fundamental part of what we do, ensuring that we cultivate trust